Nsabp Foundation, Inc.
Records under this name other than the patents Nsabp Foundation, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.
Showing 1 to 10 of 10 · Back to Nsabp Foundation, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,930,104 | Predicting response to chemotherapy using gene expression markers Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,067,178 | Gene expression markers for prediction of patient response to chemotherapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,868,352 | Predicting response to chemotherapy using gene expression markers Formerly held Term ended Term ended Mar 13, 2026 · From the USPTO record | Term ended | Term ended Mar 13, 2026 | From the USPTO record |
| US 7,622,251 | Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response Term ended Term ended Nov 4, 2025 · High confidence | Term ended | Term ended Nov 4, 2025 | High confidence |
| US 7,526,387 | Expression profile algorithm and test for cancer prognosis Formerly held Term ended Term ended Sep 17, 2025 · From the USPTO record | Term ended | Term ended Sep 17, 2025 | From the USPTO record |
| US 7,723,033 | Prediction of likelihood of cancer recurrence Formerly held Term ended Term ended Jun 17, 2025 · From the USPTO record | Term ended | Term ended Jun 17, 2025 | From the USPTO record |
| US 10,619,215 | Prediction of likelihood of cancer recurrence Formerly held Term ended Term ended Aug 13, 2024 · From the USPTO record | Term ended | Term ended Aug 13, 2024 | From the USPTO record |
| US 7,056,674 | Prediction of likelihood of cancer recurrence Formerly held Term ended Term ended Aug 4, 2024 · From the USPTO record | Term ended | Term ended Aug 4, 2024 | From the USPTO record |
| US 7,939,261 | Expression profile algorithm and test for cancer prognosis Formerly held Term ended Ended no later than Jun 30, 2024 · From the USPTO record | Term ended | Ended no later than Jun 30, 2024 | From the USPTO record |
| US 10,166,210 | Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin Lapsed on the fee record Ended Jan 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 1, 2023 | From the USPTO record |